Glaxosmithkline PLC is 10% at THERAVANCE INC (THRX). They have made 48 open-market trades across 26 companies since 2009, most recently 2021-07-02.
37 open-market purchases totalling $1.6B since 2010, against 11 sales. Across 35 scored buys the stock is down 1.9% at ninety days, and 3.5 points behind the S&P over the same stretch.
35 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 14% | 20% | 23% |
| Avg Move | -7.2% | -2.2% | -1.9% |
| Alpha | -6.8% | -3.5% | -3.5% |
| Scored | 35 | 35 | 35 |
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 100% | 80% | 50% |
| Avg Move | -12.4% | -6.7% | -1.7% |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CVRX | BUY | 2021-07-02 | 2021-07-06 | $18.00 | $5.0M | -13.0% | -8.1% | -29.6% |
| CVRX | BUY | 2021-07-02 | 2021-07-06 | $0.18 | $50K | -13.0% | -8.1% | -29.6% |
| INVA | SELL | 2021-05-20 | 2021-05-24 | $12.25 | $392.1M | -3.8% | -1.8% | +15.9% |
| DBTX | BUY | 2021-02-17 | 2021-02-19 | $18.00 | $2.7M | -9.8% | -30.2% | -56.6% |
| GNCA | BUY | 2020-07-24 | 2020-07-30 | $2.25 | $2.8M | -17.0% | -29.2% | -33.6% |
| PAND | BUY | 2020-07-21 | 2020-07-22 | $18.00 | $6.5M | -4.5% | -0.4% | -39.1% |
| BCYC | SELL | 2020-07-14 | 2020-09-18 | $19.37 | $151K | -4.8% | -5.3% | -4.4% |
| NKTX | BUY | 2020-07-14 | 2020-07-16 | $18.00 | $15.0M | -26.1% | -27.1% | -19.2% |
| TPTX | BUY | 2020-05-21 | 2020-05-26 | $60.00 | $5.0M | -3.1% | +3.2% | +11.6% |
| PGNY | SELL | 2020-05-20 | 2020-05-21 | $25.75 | $103.0M | -3.2% | -3.2% | +29.6% |
| PRNB | BUY | 2019-10-18 | 2019-10-22 | $28.00 | $10.0M | +13.2% | -1.3% | +91.5% |
| TPTX | BUY | 2019-09-10 | 2019-09-12 | $45.00 | $8.0M | -10.7% | -20.5% | +17.9% |
| MORF | BUY | 2019-07-01 | 2019-07-02 | $15.00 | $5.0M | -8.3% | +0.5% | -20.2% |
| GNCA | BUY | 2019-06-24 | 2019-06-26 | $3.50 | $6.5M | -3.7% | -11.2% | -15.9% |
| BCYC | BUY | 2019-05-28 | 2019-05-30 | $14.00 | $5.4M | +0.0% | -16.8% | -43.4% |
| TPTX | BUY | 2019-04-22 | 2019-04-24 | $18.00 | $5.8M | +19.8% | +45.3% | +38.9% |
| CCXI | SELL | 2018-10-16 | 2018-10-18 | $11.69 | $171.7M | -1.7% | -18.7% | +5.2% |
| PRNB | BUY | 2018-09-18 | 2018-09-20 | $17.00 | $4.6M | -6.7% | -17.9% | -8.5% |
| LQDA | BUY | 2018-07-30 | 2018-08-01 | $11.00 | $1.6M | +20.8% | +38.3% | +68.9% |
| SPRO | BUY | 2018-07-17 | 2018-07-17 | $12.50 | $1.0M | -7.6% | -12.1% | -18.3% |
| TBIO | BUY | 2018-07-02 | 2018-07-03 | $13.00 | $3.5M | -0.1% | -7.5% | -7.5% |
| SPRO | BUY | 2017-11-06 | 2017-11-07 | $14.00 | $6.0M | +15.7% | -16.1% | -5.8% |
| HTGM | SELL | 2017-03-27 | 2017-03-30 | $10.15 | $3.0M | -16.0% | -32.9% | -58.8% |
| CRSP | BUY | 2016-10-24 | 2016-10-26 | $14.00 | $931K | -1.7% | +31.9% | +22.5% |
| TBPH | BUY | 2016-03-14 | 2016-03-15 | $23.03 | $30.0M | +3.2% | +33.3% | +33.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| CRSP | 3,154,127 | $155.4M |
| THRX | 32,005,260 | $129.9M |
| PAND | 1,538,724 | $92.4M |
| MORF | 1,469,950 | $83.8M |
| CCXI | 7,343,492 | $78.1M |
| PATH | 4,168,017 | $53.5M |
| ANAC | 2,771,374 | $28.2M |
| LQDA | 475,604 | $16.3M |
| CNCE | 1,356,533 | $11.4M |
| TBIO | 2,974,132 | $9.6M |
| BCYC | 1,913,678 | $6.6M |
| FULC | 1,785,714 | $6.5M |
| DBTX | 1,033,663 | $5.1M |
| OMED | 2,607,546 | $2.3M |
| SPRO | 1,934,006 | $2.1M |
| CVRX | 1,007,583 | $1.3M |
| EPIX | 4,559,235 | $917K |
| AGTC | 1,436,448 | $565K |
| HTGM | 792,781 | $381K |
| GNCA | 4,626,389 | $236K |
| NKTX | 79,090 | $143K |
| HGSI | 171,070,522 | — |
| MAXY | 1,433,361 | — |
| Total | $5.5B |
Shares reported on the most recent Form 4, priced at the 2021-07-06 close. 2 holdings could not be priced and are excluded from the total.
| Scored | 10 | 10 | 10 |